AstraZeneca Contracts With Emergent BioSolutions for its COVID-19 Vaccine
Maryland-based Emergent BioSolutions has signed an $87 million contract with AstraZeneca to support development and production of the UK company’s COVID-19 vaccine, one of the leading candidates in the global race for an effective product.
Under the agreement, Emergent will produce large quantities of drug substances for the vaccine at its Baltimore Bayview facility and will provide analytical testing and other product development services at its Gaithersburg, Md., plant.
AstraZeneca’s vaccine candidate, AZD1222, which the company licensed from the University of Oxford in May, is one of five picked by the Trump administration for evaluation under Operation Warp Speed, an initiative aimed at accelerating the development of coronavirus countermeasures (DID, June 4).
The UK drugmaker also received $1.2 billion from HHS’ Biomedical Advanced Research and Development Authority (BARDA) to support the vaccine’s development and production. The contract ensures that the U.S. will receive 300 million doses (DID, May 22). — James Miessler
Upcoming Events
-
07May
-
14May
-
30May